Cash Cash Equivalents - Lytix Biopharma AS (OSE:LYTIX) - Alpha Spread
L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 7.54 NOK -1.82% Market Closed
Market Cap: 374.1m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lytix Biopharma AS
Cash & Cash Equivalents Peer Comparison

Comparables:
HBC
B
BGBIO
AZT
N
NYKD
T
TRMED

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Cash & Cash Equivalents
kr27.4m
CAGR 3-Years
-1%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Cash & Cash Equivalents
kr22.2m
CAGR 3-Years
-46%
CAGR 5-Years
-10%
CAGR 10-Years
36%
B
Bergenbio ASA
OSE:BGBIO
Cash & Cash Equivalents
kr117.3m
CAGR 3-Years
-44%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Cash & Cash Equivalents
kr173m
CAGR 3-Years
2%
CAGR 5-Years
44%
CAGR 10-Years
23%
N
Nykode Therapeutics ASA
OSE:NYKD
Cash & Cash Equivalents
$147.3m
CAGR 3-Years
-6%
CAGR 5-Years
30%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Cash & Cash Equivalents
kr41.8m
CAGR 3-Years
-48%
CAGR 5-Years
-38%
CAGR 10-Years
N/A

See Also

What is Lytix Biopharma AS's Cash & Cash Equivalents?
Cash & Cash Equivalents
27.4m NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Cash & Cash Equivalents amounts to 27.4m NOK.

What is Lytix Biopharma AS's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-11%

Over the last year, the Cash & Cash Equivalents growth was -71%. The average annual Cash & Cash Equivalents growth rates for Lytix Biopharma AS have been -1% over the past three years , -11% over the past five years .

Back to Top